Frontiers in Medicine (Jun 2021)
Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD
- Vanda Marques,
- Marta B. Afonso,
- Nina Bierig,
- Filipa Duarte-Ramos,
- Filipa Duarte-Ramos,
- Álvaro Santos-Laso,
- Raul Jimenez-Agüero,
- Emma Eizaguirre,
- Luis Bujanda,
- Luis Bujanda,
- Maria J. Pareja,
- Rita Luís,
- Adília Costa,
- Mariana V. Machado,
- Mariana V. Machado,
- Cristina Alonso,
- Enara Arretxe,
- José M. Alustiza,
- José M. Alustiza,
- Marcin Krawczyk,
- Marcin Krawczyk,
- Frank Lammert,
- Dina G. Tiniakos,
- Dina G. Tiniakos,
- Bertram Flehmig,
- Helena Cortez-Pinto,
- Helena Cortez-Pinto,
- Jesus M. Banales,
- Jesus M. Banales,
- Jesus M. Banales,
- Rui E. Castro,
- Andrea Normann,
- Cecília M. P. Rodrigues
Affiliations
- Vanda Marques
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
- Marta B. Afonso
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
- Nina Bierig
- Mediagnost, GmbH, Reutlingen, Germany
- Filipa Duarte-Ramos
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
- Filipa Duarte-Ramos
- EPIUnit–Instituto de Saúde Pública, Universidade do Porto, Oporto, Portugal
- Álvaro Santos-Laso
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
- Raul Jimenez-Agüero
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
- Emma Eizaguirre
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
- Luis Bujanda
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
- Luis Bujanda
- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain
- Maria J. Pareja
- Hospital de Valme, Sevilla, Spain
- Rita Luís
- Department of Pathological Anatomy, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
- Adília Costa
- Department of Pathological Anatomy, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
- Mariana V. Machado
- Faculdade de Medicina, Clinica Universitária de Gastrenterologia, Universidade de Lisboa, Lisbon, Portugal
- Mariana V. Machado
- Department of Gastroenterology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
- Cristina Alonso
- 0OWL Metabolomics, Bizkaia Technology Park, Derio, Spain
- Enara Arretxe
- 0OWL Metabolomics, Bizkaia Technology Park, Derio, Spain
- José M. Alustiza
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
- José M. Alustiza
- 1Radiology Service, Osatek, Donostia, Spain
- Marcin Krawczyk
- 2Department of Medicine II, Saarland University Medical Center, Homburg, Germany
- Marcin Krawczyk
- 3Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland
- Frank Lammert
- 2Department of Medicine II, Saarland University Medical Center, Homburg, Germany
- Dina G. Tiniakos
- 4Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
- Dina G. Tiniakos
- 5Department of Pathology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece
- Bertram Flehmig
- Mediagnost, GmbH, Reutlingen, Germany
- Helena Cortez-Pinto
- Faculdade de Medicina, Clinica Universitária de Gastrenterologia, Universidade de Lisboa, Lisbon, Portugal
- Helena Cortez-Pinto
- Department of Gastroenterology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
- Jesus M. Banales
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
- Jesus M. Banales
- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain
- Jesus M. Banales
- 6IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
- Rui E. Castro
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
- Andrea Normann
- Mediagnost, GmbH, Reutlingen, Germany
- Cecília M. P. Rodrigues
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
- DOI
- https://doi.org/10.3389/fmed.2021.683250
- Journal volume & issue
-
Vol. 8
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease where liver biopsy remains the gold standard for diagnosis. Here we aimed to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor 1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with the metabolome.Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD, 31 controls) and correlated with clinical data, histology, genetic parameters, and serum metabolomics.Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC 0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between obese and non-obese healthy controls, suggesting that obesity is not a confounding factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis (NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC 0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p < 0.05), but combination with international normalized ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01).Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis.
Keywords